The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Compare prescription-product growth with an earnings outlook only after matching the reporting period, geography, portfolio scope and accounting basis. Then follow the company’s bridge from sales to earnings: volume, realized price, rebates and discounts, product mix, currency, acquisitions or divestitures, operating costs, taxes, share count and unusual items. A product can grow rapidly while earnings grow more slowly—or fall—when those other factors move against it.
The examples below use company-reported results and guidance from Pfizer, Eli Lilly, Bristol Myers Squibb and Johnson & Johnson in 2026. They illustrate how to read disclosures, not industry averages, investment recommendations or promises of future performance.
What this comparison actually measures
A prescription drug’s sales growth is a revenue metric for one product, indication, geography or portfolio. An earnings outlook usually covers the entire company and forecasts earnings per share (EPS), often on an adjusted or non-GAAP basis. The two figures answer different questions:
- Product sales growth: How much recognized revenue changed versus a stated comparison period.
- Total revenue guidance: Management’s expected sales for a quarter or year, including every product and any portfolio changes included in the outlook.
- EPS guidance: Expected profit attributable to each diluted share after costs, taxes, financing effects, share-count changes and specified adjustments.
Sales growth is therefore an input to earnings, not a direct forecast of earnings. A medicine can sell more units but generate less revenue per unit after rebates, discounts or price reductions. A company can report strong revenue while spending heavily on launches, research or acquisitions. Conversely, flat sales can coexist with higher EPS if costs, taxes or share count decline.
#1 Best Overall
Use management’s guidance as a dated range based on stated assumptions. It is not a guarantee, and it can change when pricing, competition, loss of exclusivity, currency, policy, tariffs, trial outcomes or other conditions change.
Step 1: Match period, geography and scope
Start by writing down exactly what each figure covers. A quarterly product result should normally be compared with quarterly company revenue and the company’s current full-year outlook only with an explicit explanation of the timing difference. Do not place one quarter’s growth beside a full-year EPS range as though they were equivalent periods.
Check the reporting period
- Record the product’s quarter or fiscal year and the prior-year period used for the growth rate.
- Record whether the outlook is for the next quarter, the full fiscal year or another period.
- Note the release date, because guidance may have been raised, reaffirmed or reduced since an earlier release.
Check geographic coverage
Worldwide product sales and sales in one country are not interchangeable. A regional price decision, reimbursement change or launch can dominate a local result while having a smaller effect on the global company. Confirm whether the company reports constant-currency or reported figures and whether the product number is worldwide, regional or limited to a channel.
Recommended Free Tools
Check portfolio scope
Identify whether the sales figure concerns one brand, several indications, a therapeutic area or an acquired portfolio. The company outlook includes products that may be growing, declining, launching or approaching loss of exclusivity. A fast-growing product may represent only a small share of total revenue, while a mature product with a large base can determine the company’s overall result.
Step 2: Identify the sales-growth basis
Growth labels describe different calculations. Read the table heading, footnotes and reconciliation before comparing percentages.
Rank #2
| Label | What it generally includes | Questions to ask |
|---|---|---|
| Reported growth | Change in the company’s stated reporting currency using reported results. | Did currency translation, acquisitions or divestitures affect the comparison? |
| Operational growth | A company-defined measure that may remove specified portfolio changes and other effects. | Which businesses or transactions were excluded, and does the definition change by company? |
| Constant-currency growth | Growth calculated using exchange rates held constant, typically to show underlying local-currency performance. | Is the rate supplied by management, and what reported result did currency produce? |
| Adjusted growth | A company-specific presentation that may exclude currency, acquisitions, divestitures or other items. | Read the footnote; “adjusted” has no universal definition. |
Johnson & Johnson’s second-quarter 2026 release presented operational sales, adjusted operational sales and estimated reported sales separately, with footnotes covering currency, acquisitions, divestitures and special-item exclusions. Pfizer defines operational variances as excluding foreign exchange. Those examples demonstrate why two percentages with similar wording may not be comparable.
Keep the figures in separate columns rather than silently substituting one for another. If a company reports 10% operational growth and 6% reported growth, the four-point difference is information about currency or the company’s other stated adjustments—not an error to average away.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Step 3: Decompose revenue into volume, price and mix
When management provides a volume-and-price bridge, use it before drawing conclusions from the headline growth rate.
Volume
Volume reflects units, prescriptions, treatment courses or another measure defined by the company. A launch, broader indication, improved access or supply availability can increase volume. Volume growth does not automatically equal revenue growth because the units may carry different net prices or discounts.
Realized price
Realized price is the amount retained after the company’s stated deductions, which can include rebates, chargebacks, discounts, returns and other adjustments. List price increases may coexist with a lower realized price if payer concessions or mandatory discounts rise.
Rank #3
Product and geographic mix
Mix changes when a larger share of sales comes from products, indications or regions with different net prices and margins. A high-volume, lower-price indication can dilute revenue per unit. Conversely, a premium product can lift revenue even if total units are nearly flat.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsCurrency
Foreign-exchange translation can raise or reduce reported revenue without changing local-market demand. Keep reported and constant-currency growth visible until you reach the company-wide guidance basis.
Eli Lilly’s second-quarter 2026 release shows why this bridge matters: worldwide revenue was $22.974 billion, up 48% year over year, driven by a 60% increase in volume and partly offset by a 13% decrease in realized prices. Those are Lilly’s figures for that quarter, not a pharmaceutical-sector benchmark. The release also discussed regional price and volume contributors and product-specific growth, allowing the reader to see that “48% growth” was not a single uniform effect.
Step 4: Bridge revenue to earnings
After estimating what sales contributed, follow every material line between revenue and EPS. A useful bridge is:
- Revenue, including product and portfolio changes.
- Cost of sales and gross or performance margin.
- Research and development, selling, general and administrative costs, and other operating expenses.
- Interest and other non-operating items where disclosed.
- Taxes and the effective tax rate.
- Diluted share count.
- Unusual or excluded charges used to reconcile reported EPS to adjusted EPS.
| Bridge item | Why it can separate sales growth from EPS growth | Evidence to locate |
|---|---|---|
| Gross margin | Manufacturing costs, royalties, launch costs and mix can make each revenue dollar more or less profitable. | Gross-margin or performance-margin commentary and guidance assumptions. |
| Research and development | Clinical programs and regulatory work can increase expense before a product contributes revenue. | Year-over-year expense change, pipeline spending and stated investment plans. |
| Selling and administration | Launch promotion, field teams, restructuring and overhead can change operating profit. | Expense guidance, restructuring notes and launch plans. |
| Taxes | A higher effective tax rate reduces EPS even when operating profit rises. | Tax-rate assumption and explanation of discrete items. |
| Share count | Buybacks reduce the denominator; equity issuance or compensation can increase it. | Diluted-share guidance or the share-count change in the outlook. |
| Unusual items | Acquisition-related costs, impairment, restructuring or in-process research and development (IPR&D) can affect reported EPS or be excluded from adjusted EPS. | Reconciliation between GAAP or reported EPS and the company’s non-GAAP measure. |
Pfizer’s discussion of 2026 adjusted EPS guidance cites expected revenue, stable gross and operating margins and a higher adjusted tax rate. Its release also identifies anticipated loss-of-exclusivity effects and policy or tariff assumptions. Lilly said its EPS guidance reflected underlying business growth but was offset by acquired IPR&D charges. These disclosures show why multiplying a product’s sales-growth percentage by last year’s EPS is not a valid forecast.
Step 5: Compare guidance ranges on the same basis
Record each outlook as a range and preserve the measure’s definition. The midpoint can help summarize a range, but it is not management’s promised result.
| Company and release | Revenue or sales outlook | EPS outlook | Product-specific information |
|---|---|---|---|
| Pfizer, full-year 2025 results and 2026 guidance, released February 2026 | 2025 revenue was $62.579 billion, down 2% reported. Reaffirmed 2026 revenue guidance: $59.5 billion–$62.5 billion. | 2025 adjusted diluted EPS was $3.22, up 4%. Reaffirmed 2026 adjusted diluted EPS guidance: $2.80–$3.00. | The release discusses loss of exclusivity, pricing, policy and tariff assumptions affecting the outlook. |
| Eli Lilly, second-quarter 2026 results, July 2026 | Q2 revenue was $22.974 billion, up 48% year over year. Updated 2026 revenue guidance: $85 billion–$87 billion. | Q2 reported EPS was $7.94 and non-GAAP EPS was $8.38. Updated 2026 non-GAAP EPS guidance: $35.50–$36.50. | Q2 growth was driven by 60% volume growth and partly offset by a 13% decline in realized prices; acquired IPR&D charges affected EPS. |
| Bristol Myers Squibb, second-quarter 2026 results, July 2026 | Raised 2026 total revenue guidance to approximately $49 billion–$50 billion. | Raised 2026 non-GAAP EPS guidance to $6.75–$7.00. | Separately raised 2026 worldwide Eliquis revenue-growth guidance to 20%–25% versus 2025. |
| Johnson & Johnson, second-quarter 2026 results and full-year guidance, July 2026 | The outlook distinguishes operational sales, adjusted operational sales and estimated reported sales. | The outlook distinguishes adjusted operational EPS and adjusted EPS. | Footnotes describe currency, acquisitions, divestitures and special-item exclusions; use the company’s definitions rather than treating the labels as interchangeable. |
For Pfizer, the 2026 revenue range midpoint is $61.0 billion and the adjusted EPS midpoint is $2.90. For Lilly, the updated 2026 revenue midpoint is $86 billion and the non-GAAP EPS midpoint is $36.00. These midpoints are simple arithmetic summaries of the published ranges; they do not remove the uncertainty around either endpoint.
GAAP, reported and non-GAAP measures
Compare GAAP with GAAP or the same company’s defined non-GAAP measure with its prior version. Do not compare one company’s adjusted EPS with another company’s reported EPS as though the adjustments were identical. If management does not provide a forward-looking GAAP figure or a reconciliation, say so and use the disclosed measure without inventing one.
Revisions
Create a dated log with the prior low end, high end, midpoint, current low end and current high end. Note whether management changed the range because of demand, pricing, currency, acquisitions, costs, taxes or an unusual charge. A raised product-sales outlook alongside an unchanged company EPS range may indicate offsets elsewhere; it is not automatically contradictory.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchA practical worksheet for your comparison
Use this sequence for any company disclosure:
- Copy the exact product figure. Include product name, indication or portfolio, geography, period, currency and whether the rate is reported, operational, constant-currency or adjusted.
- Copy total revenue and EPS guidance. Record low and high ends, measure type, release date and whether the outlook is quarterly or annual.
- Normalize the scope. Mark mismatches such as a regional product versus worldwide revenue, a quarter versus a full year, or a brand versus a diversified portfolio.
- Build the sales bridge. Enter volume, realized price, rebates or discounts, mix, currency and portfolio transactions when disclosed.
- Build the earnings bridge. Enter gross margin, operating expenses, R&D, taxes, share count and unusual items.
- Calculate a range midpoint only as a reference. Keep the published endpoints beside it and never present the midpoint as a forecast.
- Read the risk section. List pricing pressure, loss of exclusivity, policy or tariff exposure, currency, trial or regulatory risk and any other factor management names.
- Write a conditional conclusion. State whether the product growth is consistent with the outlook under the company’s assumptions, and identify the offsets or dependencies that prevent a one-to-one inference.
How to interpret common patterns
High product growth and modest EPS growth
This pattern can be consistent when the product is still a small part of the portfolio, realized prices are falling, launch and R&D expenses are rising, taxes are higher or unusual charges reduce EPS. Check the revenue contribution and margin, not just the percentage growth rate.
Best Value
High product growth and lower total-company revenue
Other products may be declining, a major product may be losing exclusivity, currency may be unfavorable or a divestiture may remove prior-year revenue. Reconcile the growing product with the rest of the portfolio and the company’s stated reported-versus-operational basis.
Revenue guidance raised but EPS guidance unchanged
Management may expect higher costs, a higher tax rate, a larger share count or an unusual charge to absorb the additional operating profit. Look for the specific bridge rather than assuming the company is inconsistent.
EPS guidance raised while product growth slows
Margin improvement, lower expenses, tax benefits, buybacks or a favorable mix can raise EPS even when a product’s sales momentum moderates. Confirm that the EPS measure is comparable with the earlier guidance and that the benefit is not a one-time item.
Free tools Windows power users keep installed
One-click scans. No signup required.
Operational growth much higher than reported growth
The gap commonly reflects currency or the company’s stated portfolio adjustments. Use the reported figure for reported-revenue reconciliation and the operational figure for the narrower underlying-performance discussion; do not blend them into a new percentage.
Common mistakes and how to correct them
- Comparing unlike periods: Replace a quarter-to-full-year comparison with matched periods, or label the timing mismatch prominently.
- Treating list price as revenue: Use realized price after disclosed rebates, discounts and other deductions.
- Ignoring mix: Separate unit growth from the products and regions generating those units.
- Assuming “adjusted” is universal: Read each company’s reconciliation and exclusions.
- Using a single point estimate: Present the low and high ends, date the range and identify its assumptions.
- Projecting profit from sales alone: Include margin, operating expenses, taxes, share count and unusual items.
- Calling examples benchmarks: Pfizer, Lilly, Bristol Myers Squibb and Johnson & Johnson figures above are company-specific disclosures for stated periods, not typical industry results.
- Repeating outdated guidance: Check the latest release and record what management raised, reaffirmed or changed.
- Presenting guidance as a promise: Attribute it to management and include the named risks and uncertainties.
How to state the conclusion responsibly
A useful conclusion answers three questions in order:
- Is the product or portfolio growth directionally consistent with the company’s revenue range on the same basis?
- Which disclosed factors bridge that revenue result to the EPS range—margin, expenses, tax, share count or unusual items?
- What assumptions or risks could make the relationship fail?
For example, a careful statement about Lilly’s second-quarter 2026 result would say that 48% worldwide revenue growth was driven by 60% volume growth but partly offset by a 13% decline in realized prices, while the full-year outlook also reflected company-wide costs and acquired IPR&D charges. It would not claim that 48% revenue growth predicts a similar EPS increase.
For Bristol Myers Squibb, the appropriate comparison is between the separately raised 20%–25% 2026 worldwide Eliquis revenue-growth outlook and the company’s raised total-revenue and non-GAAP EPS ranges. The product range supports a contribution to the outlook, but the release’s company-wide figures still include every other product, expense, tax and adjustment.
For Pfizer, the 2025 result and reaffirmed 2026 ranges show why direction matters: reported 2025 revenue declined 2% while adjusted diluted EPS increased 4%, and management’s 2026 ranges were below the prior-year revenue and EPS levels at their midpoints. That combination cannot be explained by product growth alone; it requires the company’s stated assumptions about pricing, exclusivity, margins, taxes and policy factors.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
